TUDCA (Tauroursodeoxycholic Acid): Benefits, Dosage, Forms & Research

What the Research Says

TUDCA has a robust evidence base as both a pharmaceutical and supplement. Pan et al. (2013) conducted a multicenter RCT showing TUDCA at 750mg/day significantly improved biochemical markers in primary biliary cholangitis patients. Rodrigues et al. (1998) established the mechanistic basis for TUDCA's cytoprotective effects through mitochondrial membrane stabilization and apoptosis inhibition. Ozcan et al. (2006) published a landmark paper in Science demonstrating that TUDCA resolves ER stress and improves insulin signaling, opening a new therapeutic avenue for metabolic diseases. Kars et al. (2010) translated these findings to humans, showing improved insulin sensitivity in obese subjects. TUDCA's dual role as both a bile acid and chemical chaperone makes it uniquely versatile among hepatoprotective agents.

Benefits of TUDCA (Tauroursodeoxycholic Acid)

• ER stress reduction — TUDCA acts as a chemical chaperone that stabilizes protein folding in the endoplasmic reticulum, preventing the unfolded protein response (UPR) that triggers hepatocyte apoptosis. Ozcan et al. (2006, mouse model) demonstrated TUDCA normalized ER stress markers and improved insulin signaling.
• Cholestasis improvement — a multicenter RCT by Pan et al. (2013, n=199) showed TUDCA at 750mg/day significantly reduced bilirubin, ALT, AST, and GGT in patients with primary biliary cholangitis over 6 months.
• Hepatocyte protection — TUDCA stabilizes mitochondrial membranes and prevents cytochrome c release, inhibiting the intrinsic apoptosis pathway. Rodrigues et al. (1998) demonstrated this anti-apoptotic mechanism in multiple liver disease models.
• Bile flow enhancement — as a hydrophilic bile acid, TUDCA displaces toxic hydrophobic bile acids (like lithocholic acid) from hepatocyte membranes, reducing their cytotoxic effects and improving overall bile composition.
• Metabolic benefits — Kars et al. (2010, n=20) showed TUDCA at 1750mg/day for 4 weeks improved insulin sensitivity by approximately 30% in obese subjects, mediated through ER stress reduction in liver and muscle tissue.

Side Effects and Safety

Safety profile: Generally Safe

Potential Side Effects

• Mild diarrhea (most common, especially at higher doses)
• Nausea or stomach discomfort
• Rare: constipation or flatulence
• Very rare: allergic skin reactions

Drug & Supplement Interactions

• May reduce absorption of cyclosporine — separate by 2 hours
• Bile acid sequestrants (cholestyramine, colestipol) reduce TUDCA absorption — separate by 4 hours
• May potentiate effects of other hepatoprotective agents
• Aluminum-containing antacids may reduce absorption